Skip to content

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

A Randomized, Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferate Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00131144
Enrollment
583
Registered
2005-08-17
Start date
1999-11-30
Completion date
2005-12-31
Last updated
2011-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy

Keywords

Diabetic retinopathy,Octreotide Acetate in Microspheres

Brief summary

The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and progression of diabetic retinopathy, intensive control of glucose is usually not achieved in clinical practice.

Interventions

DRUGOctreotide Acetate in Microspheres 20 mg
DRUGPlacebo

Sponsors

Novartis
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Males and females with type 1 and type 2 diabetes mellitus * Moderately severe or severe NPDR or mild PDR in at least one eye: * with an Early Treatment Diabetic Retinopathy Study (ETDRS) visual score of \> 35 letters; and * not previously treated with scatter photocoagulation. * HbA1c \< 13% at study entry

Exclusion criteria

* Condition which could interfere with the assessment of retinopathy progression * History of symptomatic gallstones without cholecystectomy * Brittle diabetes or history of severe hypoglycemia unawareness * Previous treatment with a somatostatin analogue

Design outcomes

Primary

MeasureTime frame
time to progression of diabetic retinopathythroughout study

Secondary

MeasureTime frame
time to development or progression of macular edema, andBaseline through end of study
time to moderate vision lossBaseline through end of study

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026